Global Healthcare Study on Hidradenitis Suppurativa
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14+
SponsorJulia Tatjana Maul
About this trial
The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with hidradenitis suppurativa. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Signed General Consent Form, or equivalent document
Confirmed diagnosis of Hidradenitis Suppurativa
Disqualifiers
Inability to provide informed consent.
Datasets with ambiguous or unclear diagnosis.
Trial population
Patient populations across world regions seen for hidradenitis suppurativa.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
International Hidradenitis Suppurativa Severity Score System (IHS4)
Clinician-assessed measure of hidradenitis suppurativa severity based on the number of inflammatory nodules, abscesses, and draining tunnels; higher scores indicate more severe disease.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.Secondary outcomes
1
Hurley Staging System
Clinician-assessed classification of hidradenitis suppurativa severity categorized as Stage I, Stage II, or Stage III.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.2
Sartorius Hidradenitis Suppurativa Severity Score (HSS)
Clinician-assessed measure of hidradenitis suppurativa severity incorporating lesion counts and anatomical involvement; higher scores indicate more severe disease.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.3
Physician Global Assessment (PGA)
Clinician-assessed global measure of hidradenitis suppurativa severity on a scale from 0 to 4, with higher scores indicating more severe disease.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.4
Dermatology Life Quality Index (DLQI)
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Julia Tatjana Maul
Lead sponsor
University of Zurich
Sponsor institution
University of Zurich
Collaborator
University Hospital, Zürich
Collaborator
Source ClinicalTrials.gov